About Multiple Sclerosis

Multiple sclerosis (MS) is an unpredictable, often disabling disease of the central nervous system that interrupts the flow of information within the brain, and between the brain and body. In patients with MS, their immune and inflammatory pathways expose nerves in the brain and spinal cord by destroying their protective insulating cover, which is known as the myelin sheath. The destruction of the myelin sheath is a process called demyelination.

For decades, researchers have been trying to find ways to repair the myelin sheath, a process called remyelination,
but advances have been elusive. Currently available therapies for MS are designed to impact the immune and inflammatory pathways and primarily function to slow disease progression. However, as the disease progresses in patients with MS, the body’s natural ability to remyelinate is reduced and the disease continues to worsen, creating a need for therapies to restart this remyelinating mechanism. NDC-1308, designed by ENDECE activates the oligodendrocyte progenitor cells to induce the myelin production process.